BBIO
BridgeBio Pharma, Inc.
BBIO has the edge over NVO overall, supported by stronger fundamentals and lower modeled downside.
NVO
Novo Nordisk A/S
NVO trails on the overall score without a compensating advantage in the available component scores.
BBIO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
BBIO's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
BBIO PE Valuation
BBIO has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
BBIO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
BBIO has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
BBIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.04 | +$1.17 |
| Q2 2026 | -$3.57 | +$0.55 |
| Q1 2026 | -$3.74 | -$0.18 |
| Q4 2025 | -$3.78 | -$0.90 |
| Q3 2025 | -$4.21 | -$1.79 |
| Q2 2025 | -$4.12 | -$1.48 |
| Q1 2025 | -$3.56 | -$0.33 |
| Q4 2024 | -$2.88 | +$1.07 |
BBIO is still losing money, but less than at its worst: $3.04 per share over the past year, against $4.21 at its worst in late 2025.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over BBIO on earnings quality, reporting a profit while its opponent remains loss making.
BBIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $353.2M | +193% |
| Q2 2026 | $243.7M | +120% |
| Q1 2026 | $194.5M | +67% |
| Q4 2025 | $154.2M | +2521% |
| Q3 2025 | $120.7M | +4318% |
| Q2 2025 | $110.6M | +5000% |
| Q1 2025 | $116.6M | -45% |
| Q4 2024 | $5.9M | +237% |
BBIO has the edge over NVO on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3.3% | +117 points |
| Q2 2026 | -44% | +78 points |
| Q1 2026 | -54% | +35 points |
| Q4 2025 | -91% | +3752 points |
| Q3 2025 | -120% | +6898 points |
| Q2 2025 | -121% | +7975 points |
| Q1 2025 | -89% | -90 points |
| Q4 2024 | -3843% | +6324 points |
BBIO's operating margin was −3.3% last quarter, up 117 points from the same quarter a year ago, near the top of its range since 2019.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over BBIO on profitability, with a higher operating margin.
BBIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$44.5M | +$65.6M |
| Q2 2026 | -$71.5M | +$9.7M |
| Q1 2026 | -$197.3M | +$1.9M |
| Q4 2025 | -$56.5M | +$138.9M |
| Q3 2025 | -$110M | +$70.7M |
| Q2 2025 | -$81.3M | -209% |
| Q1 2025 | -$199.2M | +$21M |
| Q4 2024 | -$195.4M | -$70.1M |
BBIO has burned cash in almost every quarter: −$370M over the past year, against −$586M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over BBIO on cash generation, producing positive trailing cash flow while its opponent burns cash.
BBIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +244K shares |
| 1 year | +2.2% | +4.2M shares |
| 3 years | +20% | +32.7M shares |
| 5 years | +34% | +49.4M shares |
| Available history | +87% | +90.9M shares |
BBIO has 196M diluted shares, up 2.2% from a year ago, despite $253M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $42.5M |
| Q2 2026 | $127.5M |
| Q1 2026 | $82.5M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $48.3M |
| Q4 2021 | $1.5M |
BBIO spent $253M buying back its own shares over the past year.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over BBIO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
BBIO Net Leverage
BBIO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
BBIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.4 | Neutral |
| Stochastic | 48.6 | Neutral |
BBIO's weekly RSI is 57 (neutral) and its Stochastic is 49 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
BBIO PE vs Healthcare Sector
BBIO has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
BBIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $70.1 | 12% above |
| 20 week MA | $75.3 | 3.9% above |
| 50 week MA | $73.0 | 7.1% above |
| 100 week MA | $58.0 | 35% above |
| 200 week MA | $41.6 | 88% above |
BBIO has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
BBIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $36.8 | $69.5 | +89% |
| 2021 | $69.5 | $40.6 | -42% |
| 2022 | $40.6 | $7.88 | -81% |
| 2023 | $7.88 | $40.4 | +412% |
| 2024 | $40.4 | $28.0 | -31% |
| 2025 | $28.0 | $75.8 | +171% |
| 2026 YTD | $75.8 | $78.2 | +3.1% |
BBIO has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.